Jan Miller - PolyPeptide Group Chief Officer
| PPGN Stock | CHF 25.65 0.85 3.21% |
Insider
Jan Miller is Chief Officer of PolyPeptide Group AG
| Age | 53 |
| Phone | 41 41 723 20 34 |
| Web | https://www.polypeptide.com |
PolyPeptide Group Management Efficiency
The company has return on total asset (ROA) of 0.0467 % which means that it generated a profit of $0.0467 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0809 %, meaning that it generated $0.0809 on every $100 dollars invested by stockholders. PolyPeptide Group's management efficiency ratios could be used to measure how well PolyPeptide Group manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Arnoud Middel | Siegfried Holding | 52 | |
| JeanMarc Fellay | Bachem Holding AG | N/A | |
| Christian Sthelin | Bachem Holding AG | N/A | |
| M Zickar | VAT Group AG | N/A | |
| Roland Schrmann | Bachem Holding AG | 59 | |
| Stephan Haferl | Comet Holding AG | 50 | |
| Luigi Cornacchia | Comet Holding AG | N/A | |
| Alain Schaffter | Bachem Holding AG | 46 | |
| J Zoller | VAT Group AG | N/A | |
| Thomas Meier | Bachem Holding AG | 55 | |
| Peter Gehler | Siegfried Holding | 65 | |
| Enno Schweinberger | Siegfried Holding | N/A | |
| Marianne Spane | Siegfried Holding | 61 | |
| Martine Clozel | Idorsia | 68 | |
| Luca Torre | Siegfried Holding | N/A | |
| Keighley Peters | Comet Holding AG | 52 | |
| Thomas Fruh | Bachem Holding AG | 66 | |
| Simon Jose | Idorsia | 58 | |
| Dionys Ven | Comet Holding AG | 55 | |
| Peter Kiechle | Siegfried Holding | 66 | |
| Andr Muller | Idorsia | 60 | |
Management Performance
| Return On Equity | 0.0809 | |||
| Return On Asset | 0.0467 |
PolyPeptide Group Leadership Team
Elected by the shareholders, the PolyPeptide Group's board of directors comprises two types of representatives: PolyPeptide Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PolyPeptide. The board's role is to monitor PolyPeptide Group's management team and ensure that shareholders' interests are well served. PolyPeptide Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PolyPeptide Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jan Miller, Chief Officer | ||
| Daniel Lasanow, Director Operations | ||
| Michael Staheli, Head Communications | ||
| Jan Christensen, Ex Officer | ||
| Neil Thompson, Director Marketing | ||
| Monika Casanova, Chief Officer | ||
| Raymond Vre, Chief Officer | ||
| Christina Vecchio, Gen Sec |
PolyPeptide Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PolyPeptide Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0809 | |||
| Return On Asset | 0.0467 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 755.81 M | |||
| Shares Outstanding | 33.12 M | |||
| Shares Owned By Insiders | 59.60 % | |||
| Shares Owned By Institutions | 29.93 % | |||
| Price To Book | 1.90 X | |||
| Price To Sales | 2.82 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for PolyPeptide Stock Analysis
When running PolyPeptide Group's price analysis, check to measure PolyPeptide Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPeptide Group is operating at the current time. Most of PolyPeptide Group's value examination focuses on studying past and present price action to predict the probability of PolyPeptide Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPeptide Group's price. Additionally, you may evaluate how the addition of PolyPeptide Group to your portfolios can decrease your overall portfolio volatility.